Cardiol Therapeutics (TSE:CRDL) Stock Price Up 0.8%

Shares of Cardiol Therapeutics Inc. (TSE:CRDL) rose 0.8% during mid-day trading on Wednesday . The company traded as high as C$2.65 and last traded at C$2.60. Approximately 87,328 shares traded hands during mid-day trading, a decline of 39% from the average daily volume of 142,417 shares. The stock had previously closed at C$2.58.

Cardiol Therapeutics Stock Up 0.8 %

The stock’s 50 day simple moving average is C$2.79 and its two-hundred day simple moving average is C$2.72. The firm has a market cap of C$181.69 million, a P/E ratio of -5.91 and a beta of 0.70. The company has a debt-to-equity ratio of 1.07, a current ratio of 2.39 and a quick ratio of 6.84.

Insider Buying and Selling at Cardiol Therapeutics

In other Cardiol Therapeutics news, Director David Elsley bought 50,000 shares of the firm’s stock in a transaction on Monday, June 24th. The stock was acquired at an average price of C$2.77 per share, with a total value of C$138,490.00. Insiders own 4.57% of the company’s stock.

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.